These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 20631489)

  • 1. Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor.
    Prulière-Escabasse V; Gomez-Roca C; Escudier E; Coste A; Besse B; Massard C; Soria JC
    Onkologie; 2010; 33(7):401-2. PubMed ID: 20631489
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.
    Socinski MA; Detterbeck FC; Rivera MP; Egan TM; Halle J; Rosenman J
    N C Med J; 1996; 57(5):281-6. PubMed ID: 8854691
    [No Abstract]   [Full Text] [Related]  

  • 3. [Role of chemotherapy in non-small cell lung carcinoma].
    Giaccone G; Dingemans AM
    Ned Tijdschr Geneeskd; 1996 May; 140(21):1111-4. PubMed ID: 8692336
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
    De Pas T; Pelosi G; de Braud F; Veronesi G; Curigliano G; Leon ME; Danesi R; Noberasco C; d'Aiuto M; Catalano G; Viale G; Spaggiari L
    J Clin Oncol; 2004 Dec; 22(24):4966-70. PubMed ID: 15611511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of non-small-cell lung carcinoma: PS2 patients' particularities].
    Deppermann KM
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S31-4S34. PubMed ID: 15687991
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chemotherapy in non-small-cell lung carcinoma. More than just promises?].
    Feliu J; Ordóñez A; Espinosa J
    Med Clin (Barc); 1994 Jun; 103(2):72-5. PubMed ID: 8051975
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
    Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is it necessary to select patients to prescribe targeted therapies in stage IV non-small-cell lung cancers?].
    Cadranel J
    Rev Pneumol Clin; 2006 Dec; 62(6 Pt 2):2S41-4. PubMed ID: 17404539
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controversies in the treatment of non-small cell lung cancer; adjuvant chemotherapy].
    Dediu M
    Pneumologia; 2001; 50(2):115-7. PubMed ID: 11584671
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse B; Le Chevalier T
    J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemotherapy in cancer of the lung].
    Gütz S
    MMW Fortschr Med; 2006 Jun; 148(22):33-4. PubMed ID: 16821578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?
    Walter T; Scoazec JY; Couderc C; Forestier J; Roche C; Chayvialle JA; Lombard-Bohas C
    Acta Oncol; 2011 Jun; 50(5):731-2. PubMed ID: 21413853
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting mTOR signaling for lung cancer therapy.
    Sun SY; Fu H; Khuri FR
    J Thorac Oncol; 2006 Feb; 1(2):109-11. PubMed ID: 17409838
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR expression and the flexibility of FLEX.
    Hirsch FR; Herbst RS
    Lancet Oncol; 2012 Jan; 13(1):3-5. PubMed ID: 22056020
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of sulfur dioxide on the nasal mucosa of mice.
    Giddens WE; Fairchild GA
    Arch Environ Health; 1972 Sep; 25(3):166-73. PubMed ID: 5048234
    [No Abstract]   [Full Text] [Related]  

  • 18. A STEPP too far for FLEX?
    Bergot E; Creveuil C; Zalcman G
    Lancet Oncol; 2012 Feb; 13(2):e51; author reply e51. PubMed ID: 22300858
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
    Sánchez-Fructuoso AI; Santín Cantero JM; Pérez Flores I; Valero San Cecilio R; Calvo Romero N; Vilalta Casas R
    Transplant Proc; 2010 Oct; 42(8):3047-9. PubMed ID: 20970606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhinitis and epistaxis in patients treated by anti-angiogenic therapy.
    Prulière-Escabasse V; Escudier E; Balheda R; Soria JC; Coste A; Massard C
    Invest New Drugs; 2009 Jun; 27(3):285-6. PubMed ID: 18754078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.